Patent Expiry

Patent/Exclusivity Expiry: RYTELO

Drug
RYTELO

Other upcoming events for HWH

Phase 2 StartPhase 2 Start: Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoiet
Phase 3 ReadoutPhase 3 Topline: An Open Label, Randomized Non-Inferiority Trial Comparing Safety and Immunogenicity of Intradermal V
Phase 3 ReadoutPhase 3 Topline: A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunog
Phase 3 ReadoutPhase 3 Topline: Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donor

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: RYTELO — HWH Patent Expiry | BioSniper